Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) while keeping ...

In a report released on May 27, Jason Butler from Citizens JMP reiterated a Buy rating on Zevra Therapeutics, Inc.

On May 23, analyst Joseph Quatrochi from Wells Fargo maintained a Buy rating on Applied Materials, Inc. (NASDAQ:AMAT) while keeping the price target of $200. The reiteration comes after the company ...

We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks ...

For this article, we compiled a list of 15 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on May 16. We listed the stocks in the order that Cramer mentioned them.

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc.

That's why more investors are switching to BexBack - a fast-growing, no-KYC futures trading platform offering up to 100x leverage, a 100% deposit bonus, and a $50 welcome bonus for new users. Whether ...

BexBack is a leading cryptocurrency derivatives platform offering up to 100x leverage on futures contracts for BTC, ETH, ADA, SOL, XRP, and over 50 other digital assets. Headquartered in Singapore ...

But, text messages weren’t the only content analyzed; photos and videos were under the microscope as well. A video found on the phone was shown to the jury, allegedly showing Adams driving by the ...

WINNIPEG - Cottage owners and disaster prevention experts in Manitoba are urging governments to develop comprehensive wildfire management plans after a pair of devastating wildfires. Close to ...

Meetings between Qantas senior managers, a group management committee (GMC) meeting and a board meeting came under the microscope in court on Wednesday. One of the meetings between Qantas ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...